| p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells H Sutterlüty, E Chatelain, A Marti, C Wirbelauer, M Senften, U Müller, ... Nature cell biology 1 (4), 207-214, 1999 | 873 | 1999 |
| In vitro and in vivo experimental models for drug screening and development for Chagas disease AJ Romanha, SL Castro, MNC Soeiro, J Lannes-Vieira, I Ribeiro, ... Memórias do Instituto Oswaldo Cruz 105, 233-238, 2010 | 398 | 2010 |
| Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it? LH Freitas-Junior, E Chatelain, HA Kim, JL Siqueira-Neto International Journal for Parasitology: Drugs and Drug Resistance 2, 11-19, 2012 | 381 | 2012 |
| Chagas disease drug discovery: toward a new era E Chatelain Journal of biomolecular screening 20 (1), 22-35, 2015 | 335 | 2015 |
| Photostabilization of Butyl methoxydibenzoylmethane (Avobenzone) and Ethylhexyl methoxycinnamate by Bis‐ethylhexyloxyphenol methoxyphenyl triazine (Tinosorb S), a New UV … E Chatelain, B Gabard Photochemistry and photobiology 74 (3), 401-406, 2001 | 299 | 2001 |
| Inhibition of smooth muscle cell proliferation and protein kinase C activity by tocopherols and tocotrienols E Chatelain, DO Boscoboinik, GM Bartoli, VE Kagan, FK Gey, L Packer, ... Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1176 (1-2), 83-89, 1993 | 227 | 1993 |
| Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and … CB Moraes, MA Giardini, H Kim, CH Franco, AM Araujo-Junior, ... Scientific reports 4 (1), 4703, 2014 | 226 | 2014 |
| Drug discovery and development for neglected diseases: the DNDi model E Chatelain, JR Ioset Drug design, development and therapy, 175-181, 2011 | 225 | 2011 |
| Chagas disease research and development: Is there light at the end of the tunnel? E Chatelain Computational and structural biotechnology journal 15, 98-103, 2017 | 187 | 2017 |
| Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds JL Siqueira-Neto, OR Song, H Oh, JH Sohn, G Yang, J Nam, J Jang, ... PLoS neglected tropical diseases 4 (5), e675, 2010 | 183 | 2010 |
| An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages JL Siqueira-Neto, S Moon, J Jang, G Yang, C Lee, HK Moon, E Chatelain, ... PLoS neglected tropical diseases 6 (6), e1671, 2012 | 179 | 2012 |
| Skin penetration and sun protection factor of five UV filters: effect of the vehicle E Chatelain, B Gabard, C Surber Skin Pharmacology and Physiology 16 (1), 28-35, 2003 | 178 | 2003 |
| Limited Ability of Posaconazole To Cure both Acute and Chronic Trypanosoma cruzi Infections Revealed by Highly Sensitive In Vivo Imaging AF Francisco, MD Lewis, S Jayawardhana, MC Taylor, E Chatelain, ... Antimicrobial agents and chemotherapy 59 (8), 4653-4661, 2015 | 149 | 2015 |
| Translational challenges of animal models in Chagas disease drug development: a review E Chatelain, N Konar Drug design, development and therapy, 4807-4823, 2015 | 138 | 2015 |
| Novel 3-Nitro-1H-1,2,4-triazole-Based Amides and Sulfonamides as Potential Antitrypanosomal Agents MV Papadopoulou, WD Bloomer, HS Rosenzweig, E Chatelain, M Kaiser, ... Journal of Medicinal Chemistry 55 (11), 5554-5565, 2012 | 125 | 2012 |
| The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern R Abdelnabi, CS Foo, D Jochmans, L Vangeel, S De Jonghe, ... Nature Communications 13 (1), 719, 2022 | 124 | 2022 |
| Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity TY Hargrove, Z Wawrzak, PW Alexander, JH Chaplin, M Keenan, ... Journal of Biological Chemistry 288 (44), 31602-31615, 2013 | 99 | 2013 |
| Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign ML Sykes, JB Baell, M Kaiser, E Chatelain, SR Moawad, D Ganame, ... PLoS neglected tropical diseases 6 (11), e1896, 2012 | 97 | 2012 |
| Phenotypic screening approaches for Chagas disease drug discovery E Chatelain, JR Ioset Expert opinion on drug discovery 13 (2), 141-153, 2018 | 93 | 2018 |
| Analogues of fenarimol are potent inhibitors of Trypanosoma cruzi and are efficacious in a murine model of Chagas disease M Keenan, MJ Abbott, PW Alexander, T Armstrong, WM Best, B Berven, ... Journal of medicinal chemistry 55 (9), 4189-4204, 2012 | 93 | 2012 |
IOSET JEAN-ROBERTDNDiVahvistettu sähköpostiosoite verkkotunnuksessa dndi.org
